Ignite Creation Date:
2024-05-06 @ 3:51 AM
Last Modification Date:
2024-10-26 @ 11:40 AM
Study NCT ID:
NCT02394873
Status:
COMPLETED
Last Update Posted:
2015-12-30
First Post:
2015-03-06
Brief Title:
A Study to Evaluate the Safety of ALLO-ASC-DFU in the Subjects With Deep Second-degree Burn Wound
Sponsor:
Anterogen Co Ltd
Organization:
Anterogen Co Ltd
Study Overview
Official Title:
A Phase 1 Clinical Study to Evaluate the Safety of Allogeneic Adipose-derived Stem Cells in the Subjects With Deep Second-degree Burn Wound
Status:
COMPLETED
Status Verified Date:
2015-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a phase I study to evaluate the safety of ALLO-ASC-DFU for the treatment of deep second-degree burn wound patients ALLO-ASC-DFU is a hydrogel sheet containing allogenic adipose-derived mesenchymal stem cells Adipose-derived stem cells release growth factors such as vascular endothelial growth factor VEGF and hepatocyte growth factor HGF which can enhance wound healing and regeneration of new tissue finally may provide a new option in treating a burn
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None